PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells

PARP inhibitors in the management of breast cancer: current data and future prospects

(2015) Luca Livraghi et al.   BMC Medicine

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function

(2015) Felix Y. Feng et al.   MOLECULAR CELL

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ovarian cancer

(2014) Gordon C Jayson et al.   LANCET

Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors

(2013) Teemu Haikarainen et al.   ACS Medicinal Chemistry Letters

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

(2012) A. G. Patel et al.   CLINICAL CANCER RESEARCH

On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1

(2012) X. Luo et al.   GENES & DEVELOPMENT

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications

(2011) S. E. Polo et al.   GENES & DEVELOPMENT

Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells

(2011) J. R. LaRocque et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes

(2010) J. N. Barker et al.   BLOOD

Histone  H2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

(2010) C. E. Redon et al.   CLINICAL CANCER RESEARCH

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

Dynamics and processes of copy number instability in human  -globin genes

(2010) R. Neumann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Deletion of PTEN Promotes Tumorigenic Signaling, Resistance to Anoikis, and Altered Response to Chemotherapeutic Agents in Human Mammary Epithelial Cells

(2009) M. I. Vitolo et al.   CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE